Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy

Although immune checkpoint blockade (ICB) therapies have achieved great progress, the patient response varies among cancers. In this study, we analyzed the potential genomic indicators contributing to ICB therapy response. The results showed that high tumor mutation burden (TMB) failed to predict re...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Ya-Ru, Liu, Chun-Jie, Hu, Hui, Yang, Mei, Guo, An-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496944/
https://www.ncbi.nlm.nih.gov/pubmed/36139377
http://dx.doi.org/10.3390/cells11182802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496944/
https://www.ncbi.nlm.nih.gov/pubmed/36139377
http://dx.doi.org/10.3390/cells11182802

Ejemplares similares